3-D virtual resection to predict lung function after VATS anatomical lung surgery
Official title: Preoperative Three-Dimensional Virtual Resection Predicts Postoperative Pulmonary Function After Anatomical Resection : A Prospective Longitudinal Study
Run by National Taiwan University Hospital · NCT07436598 · Data updated 2026-11-12
The study will test whether a 3-D virtual resection from thin-slice CT scans can better predict lung function after VATS lobectomy or segmentectomy for people with non-small cell lung cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Status | Recruiting |
| Started | April 7, 2026 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT07436598 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 with non-small cell lung cancer who are scheduled for VATS lobectomy or segmentectomy at National Taiwan University Hospital/NTU Cancer Center and can undergo thin-slice CT and PFTs are ideal candidates.
✕Probably not a fit
Patients with COPD, those not undergoing VATS anatomical resection (for example open thoracotomy), or those unable to obtain the required CT or PFT data are unlikely to benefit from this predictive tool.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, multicenter longitudinal cohort recruits 60 patients scheduled for VATS anatomical resection (30 lobectomy, 30 segmentectomy). Preoperative thin-slice (1 mm) chest CT and standard pulmonary function tests are performed within 30 days before surgery, and a patient-specific 3-D model is reconstructed using Synapse 3-D. Investigators perform a virtual resection to calculate the planned resected ventilated lung volume fraction (pRVLVF) based on well-aerated lung (–950 to –700 HU). Patients undergo standard VATS surgery and have follow-up PFTs at 3, 6, and 12 months to compare predicted versus actual postoperative pulmonary function.
Why it matters
Potential benefit: If successful, this method could provide more accurate individualized predictions of postoperative lung function to improve surgical decision-making and patient safety.
How similar studies have gone: Imaging-based and volumetric prediction methods have shown promise in prior work, but full clinical validation of 3-D virtual resection to predict postoperative function remains limited and is still being established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients scheduled for video-assisted thoracoscopic (VATS) lobectomy or segmentectomy at National Taiwan University Hospital or NTU Cancer Center. * Age between 18 and 80 years. * Patients who have signed the informed consent form agreeing to provide imaging data for 3D modeling. Exclusion Criteria: * Age younger than 18 or older than 80 years. * Patients not scheduled for VATS lobectomy or segmentectomy. * Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD). * Patients unable or unwilling to sign the informed consent form. * Vulnerable populations.
Where it's running
-
National Taiwan University Cancer Center
Taipei, Taiwan Recruiting
Study contacts
- Study coordinator: Chih-Hsiang Chang, MD
- Email: thenightdeity@gmail.com
- Phone: +886-0972653384
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Impact of Exercise on Tumor Immunity in NSCLC Patients Receiving Neoadjuvant Chemo-Immunotherapy
A structured exercise program is being tested to see if it boosts immune cells in the tumor for patients with resectable NSCLC undergoing pre-surgery chemo-immunotherapy.
-
Low-Dose CT Lung Cancer Screening in Kuwait: Feasibility and Uptake
This pilot tests whether offering low-dose CT lung cancer screening to high-risk adults in Kuwait is workable and acceptable, with about 500 participants completing a baseline scan.
-
Does the time of day for PD-1/PD-L1 therapy affect response in NSCLC and HNSCC
In people with advanced NSCLC or resectable head and neck cancer, this study tests whether receiving PD-1/PD-L1 therapy in the morning versus the afternoon changes treatment outcomes.
-
Romiplostim N01 plus ATRA for persistent chemotherapy-induced low platelets after remission from gynecologic, breast, or lung cancer
This trial tests whether adding ATRA to Romiplostim N01 helps people keep a safe platelet count after finishing chemotherapy for certain cancers.
-
PF-08634404 Alone or with chemotherapy in early-stage or locally advanced NSCLC
This study tests PF-08634404 by itself or with chemotherapy in adults with early-stage or locally advanced non-small cell lung cancer that may be surgically removable or were candidates for additional therapy after initial treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.